Ventrus Biosciences Inc. (VTUS)

[sons4]

Could be switched from prescription to OTC, that's huge imo!! You can play this stock for early 2012 or hold for all 3 products to come out and see where they take this stock. If all goes right with the trials here and abroad, the potential is mindboggling!

The U.S. composition-of-matter patent on the iferanserin ointment expires in 2015, but existing legislation would add another five years of market exclusivity. “If that’s the case, we have an ideal product that could be switched from a prescription base to an over-the-counter product,” he says. On the other hand, Ventrus has filed new concentration-range patents which, if issued, would grant the hemorrhoid product 20 years of market exclusivity.

Dr. Ellison says Ventrus has milestones planned in each of the next six quarters, which either “reduces risk or exemplifies progress.”

http://biotuesdays.com/2011/01/25/ventru...